Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A combination of two immunotherapy drugs showed efficacy in the treatment of advanced melanoma in a phase 3 clinical trial.
Opdivo plus relatlimab delayed disease progression compared with Opdivo alone.
An advisory panel reviewed follow-up data on checkpoint inhibitors, voting to maintain four approvals and rescind two.
In a small study, 80% of participants treated with Cabometyx and Opdivo underwent successful surgery.
People diagnosed with advanced melanoma may soon have a new treatment option that combines two immunotherapy drugs.
More people treated with Opdivo plus Yervoy reached the 6.5-year survival mark than those treated with either drug alone.
Checkpoint inhibitor doubled disease-free survival time after surgery.
Opdivo plus chemotherapy led to a significant improvement in overall survival.
However, a majority of these chronic immune-related side effects were mild.
Altering gut bacteria may help overcome resistance to checkpoint inhibitors in people with melanoma and other cancers.
Opdivo plus Cabometyx reduced the risk of death by 40%.
The immunotherapy combination slowed disease progression and reduced the risk of death by 40%.
A larger Phase II trial has been launched to evaluate the combination’s efficacy and safety.
Keytruda plus chemotherapy should be a new standard of care as first-line therapy in patients with esophageal cancer, say researchers.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.